Fundamental Data for NKTR

NEKTAR THE(NSDQ:NKTR)

Nektar Therapeutics, formerly Inhale Therapeutic Systems, Inc., enables the development of high-value pharmaceutical products based on its leading drug delivery technologies. Nektar''s expanded technology and development expertise allows it to develop and offer to partners new product opportunities, solve more development challenges, and realize the full potential of their therapeutics from new molecular entities to life-cycle management products.

# Employees: 338

Address: 201 Industrial Road,San Carlos,CA,USA

Phone: 650 631-3100

Fax: 650 631-3150

Website: www.nektar.com

Email: Investors@nektar.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Robert B. Chess (Chmn.; Dir.)

Howard W. Robin (Presi.; C.E.O.; Dir.)

John Nicholson (Sr. V.P.; C.F.O.)

Gil M. Labrucherie (Sr. V.P.; Genl. Counsel.; Sec.)

Michael A. Brown (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/23/2010

Mean EPS (Next Qtr): $0.11

Mean EPS (Year): ($0.98)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 9

Shares Performance

Period	NKTR	Compare to S&P
YTD	54.86 %	28.15 %
4 Weeks	6.03 %	0.66 %
12 Weeks	2.62 %	-4.44 %

Shares Information

Analyst Coverage: Y

Avg Volume: 488049

Shares Outstanding: 92M

Market Cap: $0.80B

52 Week High: $10.47

52 Week Low: $4.03

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 8/23/2000 NKTR split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 5.71 %

EPS Growth in Last Year: 17.50 %

Sales Growth in Last Quarter: -21.29 %

Sales Growth in Last Quarter: -52.32 %

Financials

Qtr Book Value: $7.52

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 13.020